Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
BACKGROUND: In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma. METHODS: In this double-blind study involving 142 patients with metastatic melanoma who had not previously received treatment, we randomly assigned patients in a 2:1 ratio to receive ipilimumab (3 mg per kilogram of body weight) combined with either nivolumab (1 mg per kilogram) or placebo once every 3 weeks for four doses, followed by nivolumab (3 mg per kilogram) or placebo every 2 weeks until the occurrence of disease progression or unacceptable toxic effects. The primary end point was the rate of investigator-assessed, confirmed objective response among patients with BRAF V600 wild-type tumors. RESULTS: Among patients with BRAF wild-type tumors, the rate of confirmed objective response was 61% (44 of 72 patients) in the group that received both ipilimumab and nivolumab (combination group) versus 11% (4 of 37 patients) in the group that received ipilimumab and placebo (ipilimumab-monotherapy group) (P<0.001), with complete responses reported in 16 patients (22%) in the combination group and no patients in the ipilimumab-monotherapy group. The median duration of response was not reached in either group. The median progression-free survival was not reached with the combination therapy and was 4.4 months with ipilimumab monotherapy (hazard ratio associated with combination therapy as compared with ipilimumab monotherapy for disease progression or death, 0.40; 95% confidence interval, 0.23 to 0.68; P<0.001). Similar results for response rate and progression-free survival were observed in 33 patients with BRAF mutation-positive tumors. Drug-related adverse events of grade 3 or 4 were reported in 54% of the patients who received the combination therapy as compared with 24% of the patients who received ipilimumab monotherapy. Select adverse events with potential immunologic causes were consistent with those in a phase 1 study, and most of these events resolved with immune-modulating medication. CONCLUSIONS: The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with nivolumab combined with ipilimumab than with ipilimumab monotherapy. Combination therapy had an acceptable safety profile. (Funded by Bristol-Myers Squibb; ClinicalTrials.gov number, NCT01927419.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Evidence for benefit of nivolumab plus ipilimumab compared to single agent ICI has also been demonstrated in patients with advanced renal cell cancer, microsatellite high/deficient mismatch repair (MSI-hi/dMMR) metastatic colorectal cancer12,14,15, hepatocellular carcinoma16, and non-small cell, EGFR/ALK wild type lung cancer17–19.”
From A Phase I/II Trial of Nivolumab plus Ipilimumab in Children and Young Adults with Relapsed/Refractory Solid Tumors: A Children's Oncology Group Study ADVL1412 (2022) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 1×
“(% [95% CI])† 44 (61 [49–72]) 4 (11 [3–25]) 12 (52 [31–73]) 1 (10 [0–45])”
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · cited 1×
“Not reported 1 (1) 1 (3) 1 (1) 1 (2) 2 (1)”
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“>ULN 15 (21) 7 (19) 24 (25) 11 (23) 35 (25)”
Self-citationImproved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 3×
“Stable disease 9 (12) 13 (35) 3 (13) 1 (10)”
Self-citationPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“M1b 22 (31) 8 (22) 27 (28) 12 (26) 39 (27)”
Self-citationNivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519 · cited 2×
“Maculopapular rash 15 (16) 3 (3) 8 (17) 0”
Self-citationIpilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · cited 4×
“Increased lipase 12 (13) 8 (9) 2 (4) 1 (2)”
InfluentialSelf-citationNivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230 · cited 2×
“Maculopapular rash 15 (16) 3 (3) 8 (17) 0”
Self-citation
Cited by
Items 601–700 of 1,008
Management of CML-blast crisis
Hehlmann, R., Saußele, S., Voskanyan, A. A., & Silver, R. T. (2016) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2016.10.005 · Cited by 88
Casadevall, D., Clavé, S., Taus, Á., Hardy-Werbin, M., Rocha, P., Lorenzo, M., Menéndez, S., Salido, M., Albanell, J., Pijuán, L., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.04.014 · Cited by 92
Nedrow, J. R., Josefsson, A., Park, S., Ranka, S., Roy, S., & Sgouros, G. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.193268 · Cited by 88
Pol, J. G., Acuña, S. A., Yadollahi, B., Tang, N., Stephenson, K. B., Atherton, M. J., Hanwell, D., El‐Warrak, A. O., Goldstein, A., Moloo, B., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1512329 · Cited by 101
Regev, A., Avigan, M. I., Kiazand, A., Vierling, J. M., Lewis, J. H., Omokaro, S. O., Di Bisceglie, A. M., Fontana, R. J., Bonkovsky, H. L., Freston, J. W., et al. (2020) · Journal of Autoimmunity · doi:10.1016/j.jaut.2020.102514 · Cited by 83
Archibald, S. J., & Allott, L. (2021) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-021-00141-0 · Cited by 102
Kluger, H. M., Barrett, J. C., Gainor, J. F., Hamid, O., Hurwitz, M. E., LaVallee, T. M., Moss, R. A., Zappasodi, R., Sullivan, R. J., Tawbi, H. A., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005921 · Cited by 102
Diab, A. K., Gogas, H. J., Sandhu, S. K., Long, G. V., Ascierto, P. A., Larkin, J., Sznol, M., Franke, F. A., Ciuleanu, T., Pereira, C., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00172 · Cited by 96
“Although up to 60% of patients with advanced melanoma respond to immune checkpoint inhibitor regimens in the first-line setting, nearly 25% of these responders will eventually progress.(3-8) High-dose interleukin-2 (IL-2) monotherapy has shown efficacy, including durable complete responses (CRs), in patients withmetas…”
BackgroundNanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A Review
Rigon, R. B., Oyafuso, M. H., Fujimura, A. T., Gonçalez, M. L., do Prado, A. H., Gremião, M. P. D., & Chorilli, M. (2015) · BioMed Research International · doi:10.1155/2015/841817 · Cited by 97
Radiation therapy and the abscopal effect: a concept comes of age
Ng, J., & Dai, T. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.01.32 · Cited by 91
Crosby, E. J., Wei, J., Yang, X. Y., Lei, G., Wang, T., Liu, C.-X., Agarwal, P., Korman, A. J., Morse, M. A., Gouin, K., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2017.1421891 · Cited by 84
Metastatic melanoma treatment: Combining old and new therapies
Davey, R. J., van der Westhuizen, A., & Bowden, N. A. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.11.011 · Cited by 103
Immune Checkpoint Inhibitors Side Effects and Management
Kourié, H. R., & Klastersky, J. A. (2016) · Immunotherapy · doi:10.2217/imt-2016-0029 · Cited by 84
Tumour cell‐intrinsic CTLA 4 regulates PD ‐L1 expression in non‐small cell lung cancer
Zhang, H., Dutta, P., Liu, J., Sabri, N., Song, Y., Li, W. X., & Li, J. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13956 · Cited by 85
Challenge of Prognostic Uncertainty in the Modern Era of Cancer Therapeutics
Temel, J. S., Shaw, A. T., & Greer, J. A. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.8573 · Cited by 89
Tandon, P., Bourassa‐Blanchette, S., Bishay, K., Parlow, S., Laurie, S. A., & McCurdy, J. D. (2018) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000213 · Cited by 88
Liu, J.-R., Yu, C.-W., Hung, P.-Y., Hsin, L.-W., & Chern, J.-W. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.03.023 · Cited by 82
Validity of data extraction in evidence synthesis practice of adverse events: reproducibility study
Xu, C., Yu, T., Furuya-Kanamori, L., Lin, L., Zorzela, L., Zhou, X., Dai, H., Loke, Y., & Vohra, S. (2022) · BMJ · doi:10.1136/bmj-2021-069155 · Cited by 82
Tumor cell-intrinsic Tim-3 promotes liver cancer via NF-κB/IL-6/STAT3 axis
Zhang, H., Song, Y., Yang, H., Liu, Z., Gao, L., Liang, X., & Ma, C. (2018) · Oncogene · doi:10.1038/s41388-018-0140-4 · Cited by 90
Gubens, M. A., Sequist, L. V. D., Stevenson, J. P., Powell, S. F., Villaruz, L. C., Gadgeel, S. M., Langer, C. J., Patnaik, A., Borghaei, H., Jalal, S. I., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.12.015 · Cited by 87
Song, P., Zhang, D., Cui, X., & Zhang, L. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13541 · Cited by 96
Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy
Ma, Y., Xia, R., Ma, X., Judson‐Torres, R. L., & Zeng, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.702287 · Cited by 100
Identifying Individual T Cell Receptors of Optimal Avidity for Tumor Antigens
Hebeisen, M., Allard, M., Gannon, P. O., Schmidt, J., Speiser, D. E., & Rufer, N. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00582 · Cited by 94
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy
Hailemichael, Y., Woods, A. N., Fu, T., He, Q., Nielsen, M. C., Hasan, F., Roszik, J., Xiao, Z., Vianden, C., Khong, H., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci93303 · Cited by 86
Immune checkpoint inhibitors: therapeutic advances in melanoma.
Márquez‐Rodas, I., Cerezuela-Fuentes, P., Soria, A., Berrocal, A., Riso, A. A., González‐Cao, M., & Martín‐Algarra, S. (2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.10.27 · Cited by 95
Teillaud, J., & Dieu‐Nosjean, M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00830 · Cited by 86
MELK Promotes Melanoma Growth by Stimulating the NF-κB Pathway
Janoštiak, R., Rauniyar, N., Lam, T. T., Ou, J., Zhu, L. J., Green, M. R., & Wajapeyee, N. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.11.033 · Cited by 89
Mulkey, F. A., Theoret, M. R., Keegan, P., Pazdur, R., & Sridhara, R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000146 · Cited by 81
Perets, R., Bar, J., Rasco, D. W., Ahn, M., Yoh, K., Kim, D.-W., Nagrial, A. M., Satouchi, M., Lee, D., Spigel, D. R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.020 · Cited by 88
Yu, Z., Chen, J., Liu, Y., Meng, Q., Liu, H., Yao, Q., Song, W., Ren, X., & Chen, X. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1095555 · Cited by 102
“It is currently widely known that immune checkpoint blockade (ICB) immunotherapy has become a promising cancer treatment (Postow et al., 2015; Khalil et al., 2016).”
BackgroundOh, A., Tran, D. M., McDowell, L. C., Keyvani, D., Barcelon, J. A., Merino, O., & Wilson, L. (2017) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2017.23.6.653 · Cited by 87
Cheng, W., Fu, D., Xu, F., & Zhang, Z. (2018) · Oncogenesis · doi:10.1038/s41389-017-0013-7 · Cited by 81
Regan, M. M., Werner, L., Rao, S., Gupte-Singh, K., Hodi, F. S., Kirkwood, J. M., Kluger, H. M., Larkin, J., Postow, M. A., Ritchings, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00345 · Cited by 80
Self-citationDa, L., Teng, Y., Wang, N., Zaguirre, K., Liu, Y., Qi, Y., & Song, F. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01671 · Cited by 89
Neoepitopes of Cancers: Looking Back, Looking Ahead
Srivastava, P. K. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0134 · Cited by 88
Wang, J., Xie, T., Wang, B., William, W. N., Heymach, J. V., El‐Naggar, A. K., Myers, J. N., & Caulín, C. (2017) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-17-0108 · Cited by 85
Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
Li, X., Song, W., Shao, C., Shi, Y., & Han, W. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0086-z · Cited by 82
Immunotherapy for cancer in the central nervous system: Current and future directions
Binder, D. C., Davis, A. A., & Wainwright, D. A. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1082027 · Cited by 83
Friedman, C. F., Clark, V., Raikhel, A. V., Barz, T., Shoushtari, A. N., Momtaz, P., Callahan, M. K., Wolchok, J. D., Chapman, P. B., Hellmann, M. D., et al. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw260 · Cited by 80
Self-citationPredictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Shen, H., Yang, E. S.-H., Conry, M., Fiveash, J. B., Contreras, C. M., Bonner, J. A., & Shi, L. Z. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.006 · Cited by 84
“patients with previously-untreated PD-L1þ melanoma did not show better clinical responses to combined anti-CTLA-4 and anti-PD-1 therapy than those with PD-L1 tumors.(25) This was corroborated by a more recent clinical trial of patients with previously-untreated stage IV or recurrent NSCLC after chemotherapy where dist…”
BackgroundResultZhang, C., Wang, J., Sun, Z., Cao, Y., Mu, Z., & Ji, X. (2021) · Cancer Science · doi:10.1111/cas.14979 · Cited by 79
Guidi, A., Codecà, C., & Ferrari, D. (2018) · Medical Oncology · doi:10.1007/s12032-018-1096-5 · Cited by 89
PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy
Long, J., Zhang, Q., & Rongxin, Z. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2017.0086 · Cited by 91
Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity
Seliger, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00999 · Cited by 84
“The first iCPI combination employed was Ipilimumab with anti-PD-1 in melanoma resulting in an increased efficacy, but also high levels of adverse events (23, 24).”
MethodRombouts, M. D., Swart, E. L., van den Eertwegh, A. J. M., & Crul, M. (2020) · Anticancer Research · doi:10.21873/anticanres.14062 · Cited by 88
Ophthalmic adverse effects of immune checkpoint inhibitors: the Mayo Clinic experience
Fortes, B. H., Liou, H., & Dalvin, L. A. (2020) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2020-316970 · Cited by 81
Holmgaard, R. B., Brachfeld, A., Gasmi, B., Jones, D. R., Mattar, M., Doman, T., Murphy, M., Schaer, D., Wolchok, J. D., & Merghoub, T. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1151595 · Cited by 77
Self-citationRegulation of Innate and Adaptive Antitumor Immunity by IAP Antagonists
Dougan, S. K., & Dougan, M. (2018) · Immunotherapy · doi:10.2217/imt-2017-0185 · Cited by 78
Dobry, A. S., Zogg, C. K., Hodi, F. S., Smith, T. R., Ott, P. A., & Iorgulescu, J. B. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2241-x · Cited by 80
Self-citationRadiotherapy and immune checkpoints inhibitors for advanced melanoma
Filippi, A. R., Fava, P., Badellino, S., Astrua, C., Ricardi, U., & Quaglino, P. (2016) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2016.06.003 · Cited by 86
Viable Pregnancy in a patient with metastatic melanoma treated with double checkpoint immunotherapy
Burotto, M., Gormaz, J. G., Samtani, S., Valls, N., Silva, R. P., Rojas, C., Portiño, S., & de la Jara, C. (2018) · Seminars in Oncology · doi:10.1053/j.seminoncol.2018.03.003 · Cited by 81
Combination Cancer Immunotherapy in Hepatocellular Carcinoma
Kudo, M. (2018) · Liver Cancer · doi:10.1159/000486487 · Cited by 81
Cacciotti, C., Choi, J. J., Alexandrescu, S., Zimmerman, M. A., Cooney, T. M., Chordas, C. A., Clymer, J. R., Chi, S. N., & Yeo, K. K. (2020) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03578-6 · Cited by 84
Immune Checkpoint Inhibitor-Induced Hypophysitis and Patterns of Loss of Pituitary Function
Jessel, S., Weiss, S. A., Austin, M., Mahajan, A. K., Etts, K., Zhang, L., Aizenbud, L., Perdigoto, A. L., Hurwitz, M. E., Sznol, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.836859 · Cited by 86
“Primary Hypothyroidism 9 (17) 1 (8) 1 (25) 0.”
BackgroundSullivan, R. J., Atkins, M. B., Kirkwood, J. M., Agarwala, S. S., Clark, J. I., Ernstoff, M. S., Fecher, L. A., Gajewski, T. F., Gastman, B., Lawson, D. H., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0362-6 · Cited by 81
Self-citationImmune checkpoint inhibitor re-challenge in patients with advanced non-small cell lung cancer
Niki, M., Nakaya, A., Kurata, T., Yoshioka, H., Kaneda, T., Kibata, K., Ogata, M., & Nomura, S. (2018) · Oncotarget · doi:10.18632/oncotarget.25949 · Cited by 80
The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma
Lee, B., Wong, A. N. M., Kee, D., Neeson, P. J., Shackleton, M. J., McArthur, G. A., & Sandhu, S. K. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw056 · Cited by 76
Eph Receptor Tyrosine Kinases in Tumor Immunity
Shiuan, E. F., & Chen, J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1521 · Cited by 76
Liede, A., Hernandez, R. K., Wade, S. W., Bo, R., Nussbaum, N. C., Ahern, E. S., Dougall, W. C., & Smyth, M. J. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1480301 · Cited by 81
SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1
Zhang, N., Dou, Y., Liu, L., Zhang, X., Liu, X., Zeng, Q., Liu, Y., Yin, M., Liu, X., Deng, H., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.01.054 · Cited by 74
Broman, K. K., Dossett, L. A., Sun, J. X., Eroglu, Z., & Zager, J. S. (2019) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2019.1607289 · Cited by 80
The miRNAs Role in Melanoma and in Its Resistance to Therapy
Varrone, F., & Caputo, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030878 · Cited by 85
Extracellular Vesicles and Tumor-Immune Escape: Biological Functions and Clinical Perspectives
Raimondo, S., Pucci, M., Alessandro, R., & Fontana, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072286 · Cited by 80
News on immune checkpoint inhibitors as immunotherapy strategies in adult and pediatric solid tumors
Melaiu, O., Lucarini, V., Giovannoni, R., Fruci, D., & Gemignani, F. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.07.001 · Cited by 79
Emerging Trends in Immunotherapy for Cancer
Mishra, A. K., Ali, A., Dutta, S., Banday, S., & Malonia, S. K. (2022) · Diseases · doi:10.3390/diseases10030060 · Cited by 88
Targeted Therapy and Immunotherapy in Melanoma
Lazaroff, J. M., & Bolotin, D. (2022) · Dermatologic Clinics · doi:10.1016/j.det.2022.07.007 · Cited by 83
Laubli, H. P., Hench, J., Stanczak, M. A., Heijnen, I., Papachristofilou, A., Frank, S., Zippelius, A., & Stenner, F. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0249-y · Cited by 86
Wang, X., Bao, Z., Zhang, X., Li, F., Lai, T., Cao, C., Chen, Z., Li, W., Shen, H., & Ying, S. (2017) · Oncotarget · doi:10.18632/oncotarget.18316 · Cited by 75
Tumor-Specific Inhibition of In Situ Vaccination by Distant Untreated Tumor Sites
Morris, Z. S., Guy, E. I., Werner, L. R., Carlson, P. M., Heinze, C. M., Kler, J. S., Busche, S. M., Jaquish, A. A., Sriramaneni, R. N., Carmichael, L. L., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0353 · Cited by 78
Tyrosine kinase inhibitors and immune checkpoint inhibitors-induced thyroid disorders
Jannin, A., Penel, N., Ladsous, M., Vantyghem, M., & Cao, C. D. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.05.015 · Cited by 83
Pavlick, A., Blazquez, A. B., Meseck, M., Lattanzi, M., Ott, P. A., Marron, T. U., Holman, R. M., Mandeli, J., Salazar, A. M., McClain, C. B., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0545 · Cited by 75
“Owing to the high tumor mutational burden, melanoma is the natural proving ground for cancer immunotherapy as shown by the early success of the immune checkpoint inhibitors ipilimumab (8), nivolumab (9), and pembrolizumab (10).”
BackgroundSelf-citationHyperthermia and immunotherapy: clinical opportunities
Hurwitz, M. (2019) · International Journal of Hyperthermia · doi:10.1080/02656736.2019.1653499 · Cited by 79
“While this combination therapy has been shown to improve relapse-free survival compared to either agent alone, this clinical benefit comes at the expense of grade 3 or 4 toxicity in approximately half of the patients, thereby limiting its use [20,21].”
BackgroundSupportive care for patients undergoing immunotherapy
Rapoport, B. L., Eeden, R. I. V., Sibaud, V., Epstein, J. B., Klastersky, J. A., Aapro, M., & Moodley, S. D. (2017) · Supportive Care in Cancer · doi:10.1007/s00520-017-3802-9 · Cited by 83
Vujanović, L., Chuckran, C. A., Lin, Y., Ding, F., Sander, C., Santos, P. M., Lohr, J., Mashadi-Hossein, A., Warren, S., White, A., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00014 · Cited by 62
Davis, K. L., Fox, E., Isikwei, E., Reid, J. M., Liu, X., Minard, C. G., Voss, S., Berg, S. L., Weigel, B. J., & Mackall, C. L. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-2164 · Cited by 75
Zimmer, L., Eigentler, T. K., Kiecker, F., Simon, J., Utikal, J., Mohr, P., Berking, C., Kämpgen, E., Dippel, E., Stadler, R., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0716-5 · Cited by 74
Ngo, M., Han, A., Lakatos, A., Sahoo, D., Hachey, S. J., Weiskopf, K., Beck, A. H., Weissman, I. L., & Boiko, A. D. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.07.004 · Cited by 74
Namikawa, K., Kiyohara, Y., Takenouchi, T., Uhara, H., Uchi, H., Yoshikawa, S., Takatsuka, S., Koga, H., Wada, N. A., Minami, H., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.09.025 · Cited by 76
Seité, S., del Mármol, V., Moyal, D., & Friedman, A. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14104 · Cited by 74
Speranza, M. C., Passaro, C., Ricklefs, F. L., Kasai, K., Klein, S. R., Nakashima, H., Kaufmann, J. K., Ahmed, A.-K., Nowicki, M. O., Obi, P., et al. (2017) · Neuro-Oncology · doi:10.1093/neuonc/nox139 · Cited by 85
Klepsch, V., Hermann‐Kleiter, N., Do-Dinh, P., Jakic, B., Offermann, A., Efremova, M., Sopper, S., Rieder, D., Krogsdam, A., Gamerith, G., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04004-2 · Cited by 81
Sagiv, O., Kandl, T. J., Thakar, S. D., Thuro, B. A., Busaidy, N. L., Cabanillas, M., Jimenez, C., Dadu, R., Graham, P. H., Debnam, J. M., et al. (2019) · Ophthalmic Plastic & Reconstructive Surgery · doi:10.1097/iop.0000000000001161 · Cited by 71
“Hypothyroidism or thyroiditis was previously reported in different studies in 6% to 15% of patients treated with ipilimumab monotherapy or in combination with nivolumab.(9,10) Orbital inflammation related to TED was reported in 3 patients treated with ipilimumab.”
ResultNishino, M., Hatabu, H., Sholl, L. M., & Ramaiya, N. H. (2017) · Radiographics · doi:10.1148/rg.2017170015 · Cited by 79
Lesage, C., Longvert, C., Prey, S., Maanaoui, S., Dréno, B., Machet, L., Zehou, O., Kramkimel, N., Jeudy, G., Skowron, F., et al. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000268 · Cited by 81
Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis
Grover, S., Dougan, M. L., Tyan, K., Giobbie‐Hurder, A., Blum, S. M., Ishizuka, J. J., Qazi, T., Elias, R., Vora, K. B., Ruan, A. B., et al. (2020) · Cancer · doi:10.1002/cncr.32966 · Cited by 83
“The incidence of diarrhea and colitis is higher using CTLA-4-blocking agents compared to PD1/ PD-L1 blocking agents,(6,12) and highest with a combination of anti-CTLA-4 and anti-PD-1 antibodies.(11,13) ICI-induced colitis shares similar phenotypical, histological, and serological characteristics with inflammatory bowe…”
BackgroundSelf-citationVulvar Melanoma: Molecular Characteristics, Diagnosis, Surgical Management, and Medical Treatment
Wohlmuth, C., & Wieser, I. (2021) · American Journal of Clinical Dermatology · doi:10.1007/s40257-021-00614-7 · Cited by 85
Risk factors for immune-related adverse events: what have we learned and what lies ahead?
Liu, X., Shi, Y., Zhang, D., Zhou, Q., Liu, J., Chen, M., Xu, Y., Zhao, J., Zhong, W., & Wang, M. (2021) · Biomarker Research · doi:10.1186/s40364-021-00314-8 · Cited by 79
Bu, M. T., Chandrasekhar, P., Ding, L., & Hugo, W. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108211 · Cited by 84
“Subsequently, the combination of anti-PD-1 and anti-CTLA-4 was approved as a first line therapy for the treatment of patients with unresectable or metastatic melanoma (Larkin et al., 2015; Postow et al., 2015).”
BackgroundSavoia, P., Astrua, C., & Fava, P. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1129478 · Cited by 90
Brown, Z. J., Heinrich, B., Steinberg, S. M., Yu, S. J., & Greten, T. F. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0298-2 · Cited by 72
Trial watch: immune checkpoint blockers for cancer therapy
Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73
Kanjanapan, Y., Day, D., Butler, M. O., Wang, L., Joshua, A. M., Hogg, D., Leighl, N. B., Razak, A. R. A., Hansen, A. R., Boujos, S., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2018.10.017 · Cited by 72
Memory-like Differentiation Enhances NK Cell Responses to Melanoma
Marín, N. D., Krasnick, B. A., Becker‐Hapak, M., Conant, L., Goedegebuure, S. P., Berrien-Elliott, M. M., Robbins, K. J., Foltz, J. A., Foster, M., Wong, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0851 · Cited by 80
“However, despite their successes, immune- and drug-related adverse effects are common and affect >50% of the patients receiving the combination therapy (38).”
BackgroundFaghfuri, E., Faramarzi, M. A., Nikfar, S., & Abdollahi, M. R. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1074862 · Cited by 76
Drug-biomarker co-development in oncology – 20 years and counting
Twomey, J. D., Brahme, N. N., & Zhang, B. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.02.002 · Cited by 86
Iorgulescu, J. B., Harary, M., Zogg, C. K., Ligon, K. L., Reardon, D. A., Hodi, F. S., Aizer, A. A., & Smith, T. R. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0067 · Cited by 75
Self-citationChen, H., Luan, X., Paholak, H. J., Burnett, J., Stevers, N. O., Sansanaphongpricha, K., He, M., Chang, A. E., Li, Q., & Sun, D. (2019) · Nanomedicine · doi:10.2217/nnm-2019-0190 · Cited by 71
“Furthermore, scientists found that tumor-associated Tregs are resistant to traditional antitumor strategies such as chemotherapy and radiotherapy [22].”
BackgroundIravani, A., Osman, M., Weppler, A. M., Wallace, R., Galligan, A., Lasocki, A., Hunter, M., Akhurst, T. J., Hofman, M. S., Lau, P. K. H., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04815-w · Cited by 73
“Notwithstanding, this cohort had poor prognostic features including 39% with brain metastases, 32% with raised LDH, and a higher proportion of patients with mucosal melanoma who have lower response rate to immunotherapy [16].”
BackgroundCell-Intrinsic Barriers of T Cell-Based Immunotherapy
Ghoneim, H. E., Zamora, A. E., Thomas, P. G., & Youngblood, B. A. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.10.002 · Cited by 71
Tan, S., Zhang, C. W.-H., & Gao, G. F. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2016.29 · Cited by 80
Metadata
- Authors
- Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., Shaheen, M., Ernstoff, M. S., Minor, D., Salama, A. K., Taylor, M., Ott, P. A., Rollin, L. M., Horak, C., Gagnier, P., Wolchok, J. D., & Hodi, F. S.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Université Paris-Sud (FR)
- Beth Israel Deaconess Medical Center (US)
- From Memorial Sloan Kettering Cancer Center (M.A.P., J.D.W.), Weill Cornell Medical College (M.A.P., J.D.W.), and New York University, Perlmutter Cancer Center (A.C.P.) — all in New York; J. Graham Brown Cancer Center, University of Louisville, Louisville, KY (J.C.); Institute Gustave Roussy, Villejuif (C.R.), Paris-Sud University, Orsay (C.R.), and Institut Universitaire du Cancer, Toulouse (N.M.) — all in France; Huntsman Cancer Institute, Salt Lake City (K.G.); Beth Israel Deaconess Medical Center (D....
- Prisma Health (US)
- Cleveland Clinic (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-21
- Volume
- 372
- Issue
- 21
- Pages
- 2006-2017
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5744258
- OpenAlex
- W2128758225
- Cited by
- 2,781
- References
- 28
- Citations by year
- 2026: 53 · 2025: 91 · 2024: 131 · 2023: 175 · 2022: 174 · 2021: 206 · 2020: 261 · 2019: 277 · 2018: 372 · 2017: 449 · 2016: 402 · 2015: 183
- FWCI
- 204.70
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- nivolumab, ipilimumab, metastatic melanoma, combination immunotherapy, immune checkpoint inhibitors, PD-1 inhibitors, CTLA-4 inhibitors, objective response rate, progression-free survival, BRAF V600 mutation, immune-related adverse events, first-line therapy, dose escalation, complete response, duration of response
- MeSH terms
- Ipilimumab, Nivolumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Double-Blind Method, Female, Humans, Male, Melanoma, Middle Aged, Disease-Free Survival, Tumor Burden, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.